EVITRADE Health System’s Latest Biotech LOI Positions It to Be a Force in the USD $30 Billion Plant-Based Pharmaceutical Industry

Vancouver, British Columbia (FSCwire) - EVITRADE Health Systems Corp. (CSE: EVA, OTCQB: AXHLF) (the “Company”) announces that it has signed a revised Letter of Intent with Cantech Molecular Research Inc. (“Cantech”).

The soon-to-be acquired Cantech and/or Cantech Intellectual Property (“IP”) specializes in systems for the manufacture of highly advanced plants grown through selective breeding (also known as cultivars) and the production of quality pharmaceutical products for use in agriculture and medicine.

With this transaction, the Company is looking to add yet another valuable and versatile asset in its ongoing bid to become an influential player in the rapidly growing plant-based pharmaceutical business. Recent industry reports indicate the global market is expected to grow from its current USD $29.7 billion in 2017 to nearly $40 billion in just five years. That represents a 6.1 percent compound annual growth rate.

“This latest deal should greatly strengthen our overall medical and biotech capabilities,” continued Mr. CK Cheung of EVA, “It’s another piece in the mosaic we are building. When complete, EVA will be able to offer a complete range of plant-based biotech, pharmaceutical and therapeutic solutions. We can ensure only the highest-quality ingredients are used in every made-to-order batch produced. This would be thanks to our ability to reproduce elite plants that maximize the perfection and potency of active plant ingredient yields. This acquisition will play a large role in that, giving us forward momentum.”

Among the progressive capabilities EVA will gain are new methods of plant breeding and manipulation at the genetic level, genetic mapping and proprietary tissue culture and haploid breeding systems will compliment those EVA has already developed or acquired.

The modern world is rapidly recognizing the value of plant-based pharmaceuticals. Already there are plant-based remedies that have challenged the supremacy of big pharmaceutical companies. However, plant-based pharmaceuticals are actually nothing new across most of the world. Humans have been using plants and herbs for medicinal purposes since the dawn of time. At least 28,000 different species of plants are currently used in the production of medicines. What is new is the application of advanced biotechnology techniques – such as those that will be employed by EVA – to improve ingredient quality and yields.

Plant-based pharmaceuticals hold two key advantages over those produced from chemicals. First, they often have fewer issues with safety and patient tolerance. As they are made from natural substances, they can have fewer side effects. The result is that the approval timeline is frequently shorter for plant-based pharmaceuticals, greatly cutting manufacturing costs and speeding the product to market.

Management continues to strive to seek optimal business and commercialization strategies for the Company, and currently various opportunities are being pursued.  The recent re-engagement of Haywood Securities as financial advisor to assist in evaluating the numerous opportunities in front of us; has the Company planning for an exciting and bright future.

Contact: CK Cheung, CEO & Director

EVITRADE Health Systems Corporation

(formerly Auxellence Health Corporation)

Email info@evahealthsystems.com

Website http://www.evahealthsystems.com

CSE Micro-site: http://thecse.com/en/listings/technology/evitrade-health-systems-corp

US OTC Markets: http://www.otcmarkets.com/stock/AXHLF/news

About EVITRADE Health (CSE: EVA, OTCQB: AXHLF)

EVITRADE (formerly Auxellence Health Corp.), was founded in 2013 to provide online “digital healthcare” services for resolving common health problems. The current markets are weight-loss, high blood pressure, high blood glucose and heart arrhythmia.

Disclaimers – Forward Looking Statements

This news release contains forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators and on the OTC Markets website which is posted on www.sedar.com, http://thecse.com/en/listings/technology/evitrade-health-systems-corp, and http://www.otcmarkets.com/stock/AXHLF/filings. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.

To view the original release, please click here

To follow EVITRADE Health Systems Corp. on your favorite social media platform or financial websites, please click on the icons below.

Maximum News Dissemination by FSCwire. https://www.fscwire.com

Copyright © 2018 FSCwire